Drug intelligence / Profile preview

oxcarbazepine + padsevonil

Development stage: Unknown
Lead developer: UCB
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of oxcarbazepine, an established anticonvulsant, and padsevonil, a novel antiseizure medication candidate. Padsevonil is a first-in-class drug with dual mechanism of action that interacts with both synaptic vesicle protein 2 (SV2) and GABA-A receptors. Oxcarbazepine is a voltage-sensitive sodium channel blocker. The combination has been studied to evaluate pharmacokinetic interactions, as oxcarbazepine is a CYP3A4 inducer and padsevonil's metabolism is primarily mediated by CYP3A4.

Targets

NaV (Voltage-gated sodium channels)BZD site (GABA-A receptor benzodiazepine site)SV2B (Synaptic vesicle glycoprotein 2B)SV2C (Synaptic vesicle glycoprotein 2C)

Beyond the preview

Go deeper on oxcarbazepine + padsevonil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxcarbazepine + padsevonil.

Explore the full profile